Method of treating HIV-1 infection utilizing a multiepitope T cell immunogen comprising gag, pol, vif and nef epitopes

Patent metadata

Field	Value
Publication number	US-11325946-B2
Application number	US-201815970216-A
Country	US
Kind code	B2
Filing date	May 3, 2018
Priority date	Jan 27, 2012
Publication date	May 10, 2022
Grant date	May 10, 2022

Abstract

The present invention relates to novel immunogens based on overlapping peptides (OLPs) and peptides derived therefrom useful for the prevention and treatment of AIDS and its related opportunistic diseases. The invention also relates to isolated nucleic acids, vectors and host cells expressing these immunogens as well as vaccines including said immunogens.

First claim

The invention claimed is:

1. A method of treating an HIV infection or a disease associated with an HIV infection in a subject in need thereof, the method comprising sequentially administering to the subject (1) a nucleic acid encoding a first immunogenic polypeptide and (2) a second immunogenic polypeptide or a nucleic acid encoding a second immunogenic polypeptide,
wherein the first immunogenic polypeptide comprises the sequences of SEQ ID NOs:1-16 adjoined by amino acid linkers,
wherein the second immunogenic polypeptide comprises the sequences of SEQ ID NOs:1-16 adjoined by amino acid linkers,
wherein the nucleic acid encoding the first immunogenic polypeptide is administered to the subject as part of an expression cassette, an expression vector, a virus, or a cell,
wherein the nucleic acid encoding the second immunogenic polypeptide is administered to the subject as part of an expression cassette, an expression vector, a virus, or a cell, and
wherein (1) the nucleic acid encoding the first immunogenic polypeptide and (2) the second immunogenic polypeptide or the nucleic acid encoding the second immunogenic polypeptide are administered in amounts effective for eliciting an immune response against HIV in the subject.

2. The method of claim 1 , wherein the subject is a human subject, and
wherein (1) the nucleic acid encoding the first immunogenic polypeptide and (2) the second immunogenic polypeptide or the nucleic acid encoding the second immunogenic polypeptide are administered to the human subject to treat AIDS, ARC, or an HIV opportunistic disease.

3. The method of claim 1 , wherein the amino acid linkers are single, dual, or triple alanine linkers, and wherein the linkers result in the formation of an AAA sequence in the junction region between adjoining sequences.

4. The method of claim 3 , wherein the first and second immunogenic polypeptides have the sequence of SEQ ID NO:99.

5. The method of claim 1 , wherein the nucleic acids encoding the first and second immunogenic polypeptides have the sequence of SEQ ID NO:100.

Assignees

• Esteve Labor Dr
• Fundacio Privada Inst De Recerca De La Sida—Caixa
• Fundacio Privada Inst De Recerca De La Side—Caixa

Inventors

• Brander Christian
• Mothe Pujadas Beatriz
• Llano Anuska

Classifications

• C12N2740/16034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C07K2319/35

  containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• A61K39/12

  Viral antigens · CPC title